Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 tri...
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
About this item
Full title
Author / Creator
for the ATAMS Study Group , ATAMS Study Group , Kappos, Ludwig, Prof , Hartung, Hans-Peter, Prof , Freedman, Mark S, Prof , Boyko, Alexey, Prof , Radü, Ernst Wilhelm, Prof , Mikol, Daniel D, MD , Lamarine, Marc, PhD , Hyvert, Yann, PhD , Freudensprung, Ulrich, MS , Plitz, Thomas, PhD and van Beek, Johan, PhD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Depletion of B lymphocytes is associated with suppression of inflammatory activity in multiple sclerosis. We aimed to assess the safety and efficacy of atacicept, a recombinant fusion protein that suppresses B-cell function and antibody production. Methods In this placebo-controlled, double-blind, 36-week, phase 2 trial (ATAMS) i...
Alternative Titles
Full title
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1512322268
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1512322268
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(14)70028-6
